Abstract
Rheumatoid arthritis (RA) is a chronic rheumatic disease, characterized by erosive and destructive arthritis, representing an important cause of disability. Interstitial lung disease is not a rare event and can be aggravated by several immunosuppressive medications. Methotrexate, once seen as a drug associated with interstitial pneumonitis, is now seen as an agent capable of slowing or preventing the progression of lung disease related to rheumatoid arthritis. Anti-TNFs currently represent the class with the greatest impact on the course of pulmonary disease in RA, with a significant increase in mortality. Among the immunobiological agents, abatacept and Rituximab stand out in relation to the pulmonary safety profile.
Highlights
Rheumatoid arthritis (RA) is a chronic rheumatic disease, of unknown etiology and essentially autoimmune in nature
The risk of RA-associated interstitial pneumonitis is higher in individuals with positive rheumatoid and / or anti-CCP factors, with frequent observation of asymptomatic patients with subclinical disease
Methotrexate, a drug considered the gold standard in the treatment of RA, has over time been implicated in the development of acute, subacute and chronic interstitial lung disease and in the progression of subclinical pulmonary fibrosis related to the underlying disease [3]
Summary
Rheumatoid arthritis (RA) is a chronic rheumatic disease, of unknown etiology and essentially autoimmune in nature. It is characterized by chronic, erosive and destructive polyarthritis, affecting mainly small peripheral joints, representing an important cause of physical disability and disability [1]. The risk of RA-associated interstitial pneumonitis is higher in individuals with positive rheumatoid and / or anti-CCP factors, with frequent observation of asymptomatic patients with subclinical disease. It usually occurs in the first five years of the disease and it may precede joint involvement in up to 20% of cases. Interstitial lung disease stands out, notably the usual interstitial
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: SunKrist Journal of Orthopedics and Musculoskeletal Disorders
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
